Xintela to develop stem cell therapy for difficult-to-heal wounds

#Regulatory

Xintela announces today that the company will develop its stem cell product XSTEM® for the treatment of difficult-to-heal (chronic) wounds. In collaboration with The Burn Center at Linköping University Hospital, Xintela has found that XSTEM has excellent wound healing capability in a preclinical model and is now planning for a clinical trial on patients with difficult-to-heal wounds.

Xintela, together with Professor Folke Sjöberg and his team at The Burn Center at Linköping University Hospital, showed that XSTEM provides excellent healing of wounds in a pig model and that the newly formed skin tissue closely resembles normal skin. XSTEM also showed less scarring compared to transplanted skin cells. Xintela is now planning for clinical studies together with the Linköping team.

– Wound healing is an exciting indication for our stem cell product XSTEM. The medical need is very high and we see a large and attractive market in an area that consumes significant healthcare resources. We can quickly enter the market with a wound healing XSTEM product because clinical studies in wound healing can be completed in a relatively short time, says Xintela's CEO Evy Lundgren-Åkerlund.

Professor Folke Sjöberg, who is very well known internationally for his burn research, and who has together with his research team has also shown success in other wound healing areas, particularly in difficult-to-heal wounds, where new methodology and new research models have been developed, says:

– Difficult-to-heal wounds, also called chronic wounds, are a comprehensive medical problem that cause a lot of pain and suffering for patients and we currently lack good treatment methods. Difficult-to-heal wounds usually have several underlying causes and therefore Xintela's XSTEM product, which can potentially have several different wound healing functions, is extremely interesting. We are very impressed with the healing potential that we have seen so far with Xintela's stem cell product XSTEM and are therefore very much looking forward to treating patients with XSTEM in clinical trials.

This information is such information that Xintela AB (publ) is obligated to publish in compliance with the EU market abuse regulation. The information was provided, through the below contact, for publication at 11:40 CET on the 20th of May, 2021.

Xintela AB (publ)
Evy Lundgren-Åkerlund, CEO
Tel: +46 46 275 65 00
Email: evy@xintela.se
Medicon Village
223 81 Lund, Sweden
www.xintela.se 

About Xintela
Xintela develops innovative and patent protected cell therapies and targeted cancer therapies based on the marker technology platform XINMARK. The platform is built on specific cell surface proteins (integrins) and more than 25 years of research and development. Xintela uses the marker technology to select and quality assure stem cells (XSTEM) to develop stem cell therapies for diseases that today lack efficient treatment options, including the joint disease osteoarthritis (OA). Xintela has built an in-house GMP-facility for manufacturing of stem cell products and is preparing a First in Human clinical study on patients with knee OA. In the oncology program, Xintela develops antibody-based therapies for treatment of aggressive tumors including glioblastoma and triple-negative breast cancer. Xintela is listed on Nasdaq First North Growth Market Stockholm since 22 March 2016. Xintela's Certified Adviser at Nasdaq First North Growth Market is Erik Penser Bank AB, +46 8-463 80 00, certifiedadviser@penser.se.


Archive

Below you will find the collected information on Xintela’s press releases, newsletters, diary events, films, media coverage and analyses.

October 11, 2022
2022 Cell & Gene Meeting on the Mesa, Carlsbad, October 11-13
2022 Cell & Gene Meeting on the Mesa, Carlsbad, October 11-13
October 6, 2022
ICRS Focus Meeting, Bologna, October 6-7
ICRS Focus Meeting Bologna, October 6-7
September 28, 2022
Nordic Life Science Days, Malmö, September 28-29, 2022
Nordic Life Science Days, Malmö, September 28-29, 2022
August 30, 2022
2nd Integrin-Targeted Drug Development Summit, Boston, August 30 - September 1
2nd Integrin-Targeted Drug Development Summit, Boston, August 30 - September 1
June 13, 2022
Bio International Convention, San Diego, June 13-16
Bio International Convention, San Diego, June 13-16
June 13, 2022
Småbolagsdagarna, Stockholm, June 13-15
Småbolagsdagarna, Stockholm, June 13-15
June 14, 2022

CEO Evy Lundgren-Åkerlund presents the company at Aktiespararnas Småbolagsdagarna 2022 (in Swedish).

June 14, 2022

Targinta's CEO Per Norlén presents the company at Aktiespararnas Småbolagsdagarna 2022 (in Swedish).

June 9, 2022

CEO Evy Lundgren-Åkerlund presents the company at BioStock Life Science Spring Summit 2022.

February 27, 2020

BioStock interview with Xintela's CMO and board member Sven Kili.

August 30, 2018

BioStock was given the opportunity to interview Sven Kili in connection with his visit to Sweden for board and strategy work in Xintela.

February 9, 2017

Dr. Marcus Keep comments on Xintelas glioblastoma project.

January 31, 2017

Xintelas Chairman of the board and strategic advisor Greg Batcheller, tells us more about Xintelas potential and prospects.

January 30, 2017

Dr. Lisa Fortier at Cornell University, New York is interviewed by BioStock about Xintelas positive results in horse study.

December 28, 2016

In the following video interview, Karin explains her role at Xintela and what she considers to be Xintela’s primary strengths.

December 13, 2016

See the interview with Claes Post, member of the board in Xintela. The interview is in swedish with english subtitles.

March 24, 2016

See the interview with Sven Kili, member of the board in Xintela. The interview is in English (introduction is in Swedish).

March 22, 2016

See an interview with Xintela's CEO Evy Lundgren-Åkerlund, after the listing ceremony at Nasdaq First North.

March 15, 2016

Investor presentation from Lund - Jan 27

January 14, 2016

Interview with Xintelas CEO

July 6, 2022
BioStock: Xintela in clinical development
June 1, 2022
BioStock Studio: Xintela's CEO comments on the upcoming share issue
April 12, 2022
BioStock: Xintela's CEO on the potential in difficult-to-heal wounds
March 4, 2022
BioStock: Xintela presents plans for 2022 in its Q4 report
January 27, 2022
BioStock Studio: Targinta provides business update prior to spin-off
January 19, 2022
BioStock: Xintela advances to clinical phase in osteoarthritis and difficult-to-heal wounds 2022
October 12, 2021
BioStock: Professor Folke Sjöberg about XSTEM for treatment of venous leg ulcers.
November 9, 2020
BioStock: Xintela’s CEO comments on the positive patent notice
June 22, 2017
Xintela covered in GEN regarding its participation in multi-million, government funded initiative to form a...
March 2, 2017
Xintela covered in Horsetalk.co.nz regarding that its stem cells are safe for use in horses
March 23, 2016
(Article in Swedish) Xintela tar behandling av ledskador och cancer till First North.
March 23, 2016
(Article in Swedish) Grundare av Xintela ser notering som viktig milstolpe
March 23, 2016
(Article in Swedish) Xintela covered in Life Science Sweden
February 24, 2016
(Article in Swedish) Rapidus: Xintela på väg till First North
December 10, 2021
Edison Group has published a research update on Xintela.
July 14, 2021
Xintela, backed by its integrin biomarker technology platform XINMARK, is a potential disrupter
November 9, 2020
A status report of the Xintela has been published by Biostock
April 12, 2018
Read the full analysis here
Top